Monitor Teva's Q1 earnings call today for margin impact details and financing strategy. Watch for regulatory updates on ecopipam NDA acceptance and Phase 3 data readouts. The deal strengthens Teva's late-stage pipeline but adds modest near-term dilution to margins.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 29 $35.39entry
- T+1 · 7mo ago −0.87%α −1.90% · $35.08
- T+5 · 7mo ago +2.37%α −0.74% · $36.23
- T+20 · 6mo ago −2.71%α −8.76% · $34.43
- T+60 · 4mo ago −11.89%α −15.62% · $31.18
Price Chart
How similar events traded
Executive Summary
Teva acquires Emalex Biosciences for $700M upfront plus up to $200M in milestones and royalties, gaining ecopipam, a late-stage Tourette syndrome therapy with positive Phase 3 data and FDA Orphan/Fast Track designations. The deal expands Teva's innovative neuroscience pipeline and aligns with its Pivot to Growth strategy, with NDA submission expected in 2H 2026 and close by Q3 2026.
Key Financial Metrics
Key Facts
- Teva to pay $700M upfront in cash for Emalex, with up to $200M in commercial milestones plus royalties.
- Ecopipam met primary endpoint in Phase 3 Tourette syndrome study (p=0.0084).
- NDA submission anticipated in 2H 2026; FDA Orphan Drug and Fast Track designations.
- Transaction expected to close by Q3 2026, subject to regulatory approvals.
- Teva will fund upfront with cash on hand and remains on track for 2027 financial targets.
Financial Impact
Upfront $700M cash payment, potential $200M milestones, and royalties; total deal value up to $900M plus ongoing royalties.
Risk Factors
- Clinical or regulatory setback for ecopipam could impair deal value.
- Competition from existing Tourette treatments (e.g., Haldol, clonidine) and pipeline candidates.
- Integration risk and potential margin dilution if milestones are paid before revenue materializes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283566 |
Track record
61 reports on TEVA
6 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers